

## **Rosetta Genomics Announces Participation in Cantor Fitzgerald's Inaugural "From Bench to Bedside" Healthcare Conference**

PRINCETON, N.J. and REHOVOT, Israel (July 1, 2015) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that company management will participate at the 2015 Inaugural "From Bench to Bedside" Healthcare Conference hosted by Cantor Fitzgerald. The conference will take place at Le Parker Meridien Hotel in New York City on Wednesday, July 8th. Ken Berlin, President and Chief Executive Officer of Rosetta Genomics, will deliver a corporate overview at 2:00 p.m. Eastern time.

Mr. Berlin's presentation will be webcast live and can be accessed by visiting the investor section of the company's website at [www.rosettagenomics.com](http://www.rosettagenomics.com). The webcast will be archived for a period of 90 days following the live webcast.

### **About Rosetta Genomics**

Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company offers core FISH, IHC and PCR-based testing capabilities and partnerships in oncology and urology that provide additional content and platforms that complement the Rosetta offerings. Rosetta's and PersonalizeDx's cancer testing services are commercially available through the Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs, respectively. For more information visit [www.rosettagenomics.com](http://www.rosettagenomics.com).

### **Forward-Looking Statement Disclaimer**

Various statements in this release concerning Rosetta's future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2014 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

**Company Contacts:**

Rosetta Genomics

Ken Berlin, President & CEO

(609) 419-9003

[investors@rosettagenomics.com](mailto:investors@rosettagenomics.com)

**Investor Contacts:**

LHA

Anne Marie Fields

(212) 838-3777

[afields@lhai.com](mailto:afields@lhai.com)

or

Bruce Voss

(310) 691-7100

[bvoss@lhai.com](mailto:bvoss@lhai.com)

###